Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Meta’s decision to eliminate its fact-checking program marks a sharp reversal for the major social media company, quickly ...

Johnson & Johnson closed $26.58 below its 52-week high ($168.85), which the company reached on September 4th.

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

One of the biggest beefs in Hollywood briefly returned to the spotlight at Sunday's Golden Globes. While presenting at the ...